The multifaceted approach exhibited by GLPs, involving the inhibition of PRMT6 signaling and the activation of NAG-1, combined with the regulation of Akt and MAPK/ERK pathways, underscores their potential as a valuable agent in combating prostate cancer. This evidence concerns the gene AKT1 and prostate carcinoma.